Table 4.
Univariate analysis of factors associated with radiation proctitis in patients receiving chemoradiotherapy
| Variable | No. of radiation proctitis/total patients (%) | P value |
|---|---|---|
| Interval | .018a , b | |
| ≤7 wks | 9/60 (15.0) | |
| >7 wks | 31/97 (32.0) | |
| Comorbidities | .619b | |
| Yes | 6/20 (30.0) | |
| No | 34/137 (24.8) | |
| Smoking | .165b | |
| Yes | 7/40 (17.5) | |
| No | 11/117 (9.4) | |
| Pelvic node irradiation | .716c | |
| Yes | 3/10 (30.0) | |
| No | 37/147 (25.2) | |
| Chemotherapy regimen | .689b | |
| 5‐FU | 17/71 (23.9) | |
| FOLFOX | 23/86 (26.7) | |
| Gender | .494b | |
| Women | 11/50 (22.0) | |
| Men | 29/107 (27.1) | |
| Age | .284b | |
| ≤60 | 24/105 (22.9) | |
| >60 | 16/52 (30.8) | |
| AJCC stage | ||
| II | 7/35 (20.0) | .399b |
| III | 33/122 (27.0) |
5‐FU, 5‐fluorouracil; FOLFOX, 5‐fluorouracil + leucovorin + oxaliplatin; AJCC, American Joint Committee on Cancer (7th edition).
a
Statistically significant.
b
Data were calculated using the χ2 test.
c
Data were calculated using the Fisher exact test.